-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The U.
S.
Food and Drug Administration (FDA) has approved Johnson & Johnson's Rybrevant as the first treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
In the United States, there are currently no targeted treatments, such as EGFR tyrosine kinase inhibitors (TKIs), which have not been approved by the FDA for the treatment of non-small cell lung cancer driven by EGFR exon 20 insertion mutations .
Most importantly, non-small cell lung cancer driven by this specific mutation usually carries a worse prognosis and lower survival rates than lung cancer driven by more common mutations .
Johnson & Johnson OncologyPeter Lebowitz, Head of Global Therapy of the R&D Center, said: "The approval of Rybrevant and the accompanying diagnostic tests address the highly unmet needs of genetically defined non-small cell lung cancer patients.
" He added: "At Johnson & Johnson, we are committed to the development of Rybrevant.
It is believed that advanced drugs targeting specific pathways can bring the greatest benefits and improve prognosis for patients with tumor changes such as EGFR and MET.
She added: "We are very pleased with the hope this new treatment option can bring to people with this particular type of lung cancer and their families.
" (cyy123.
com)
The U.
S.
Food and Drug Administration (FDA) has approved Johnson & Johnson's Rybrevant as the first treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) exon 20 insertion mutations.
In the United States, there are currently no targeted treatments, such as EGFR tyrosine kinase inhibitors (TKIs), which have not been approved by the FDA for the treatment of non-small cell lung cancer driven by EGFR exon 20 insertion mutations .
Most importantly, non-small cell lung cancer driven by this specific mutation usually carries a worse prognosis and lower survival rates than lung cancer driven by more common mutations .
Johnson & Johnson OncologyPeter Lebowitz, Head of Global Therapy of the R&D Center, said: "The approval of Rybrevant and the accompanying diagnostic tests address the highly unmet needs of genetically defined non-small cell lung cancer patients.
" He added: "At Johnson & Johnson, we are committed to the development of Rybrevant.
It is believed that advanced drugs targeting specific pathways can bring the greatest benefits and improve prognosis for patients with tumor changes such as EGFR and MET.
She added: "We are very pleased with the hope this new treatment option can bring to people with this particular type of lung cancer and their families.
" (cyy123.
com)
